Drugs / BB-1709
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06241898 | Oct 2023 → Jun 2026 overdue | neoplasm | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-1709 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241898 ↗ |
| Route | Intravenous | “BB-1709 will be administered as an intravenous infusion” NCT06241898 ↗ |